Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis

Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit−risk profile. https://bit.ly/3SbisW3

Detalles Bibliográficos
Autores principales: Chalmers, James D., Metersky, Mark L., Feliciano, Joseph, Fernandez, Carlos, Teper, Ariel, Maes, Andrea, Hassan, Mariam, Chatterjee, Anjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152260/
https://www.ncbi.nlm.nih.gov/pubmed/37143828
http://dx.doi.org/10.1183/23120541.00695-2022
_version_ 1785035715322576896
author Chalmers, James D.
Metersky, Mark L.
Feliciano, Joseph
Fernandez, Carlos
Teper, Ariel
Maes, Andrea
Hassan, Mariam
Chatterjee, Anjan
author_facet Chalmers, James D.
Metersky, Mark L.
Feliciano, Joseph
Fernandez, Carlos
Teper, Ariel
Maes, Andrea
Hassan, Mariam
Chatterjee, Anjan
author_sort Chalmers, James D.
collection PubMed
description Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit−risk profile. https://bit.ly/3SbisW3
format Online
Article
Text
id pubmed-10152260
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-101522602023-05-03 Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis Chalmers, James D. Metersky, Mark L. Feliciano, Joseph Fernandez, Carlos Teper, Ariel Maes, Andrea Hassan, Mariam Chatterjee, Anjan ERJ Open Res Research Letters Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit−risk profile. https://bit.ly/3SbisW3 European Respiratory Society 2023-05-02 /pmc/articles/PMC10152260/ /pubmed/37143828 http://dx.doi.org/10.1183/23120541.00695-2022 Text en Copyright ©The authors 2023 https://creativecommons.org/licenses/by/4.0/This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.
spellingShingle Research Letters
Chalmers, James D.
Metersky, Mark L.
Feliciano, Joseph
Fernandez, Carlos
Teper, Ariel
Maes, Andrea
Hassan, Mariam
Chatterjee, Anjan
Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
title Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
title_full Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
title_fullStr Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
title_full_unstemmed Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
title_short Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
title_sort benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
topic Research Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152260/
https://www.ncbi.nlm.nih.gov/pubmed/37143828
http://dx.doi.org/10.1183/23120541.00695-2022
work_keys_str_mv AT chalmersjamesd benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis
AT meterskymarkl benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis
AT felicianojoseph benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis
AT fernandezcarlos benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis
AT teperariel benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis
AT maesandrea benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis
AT hassanmariam benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis
AT chatterjeeanjan benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis

Ejemplares similares